CASSAVA SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.94 USD | -3.58% |
|
-6.30% | -11.42% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 89.54 | 238.4 | 1,749 | 1,233 | 949.3 | 956.6 | - | - |
| Enterprise Value (EV) 1 | 89.54 | 238.4 | 1,749 | 1,233 | 949.3 | 956.6 | 956.6 | 956.6 |
| P/E ratio | -19.3 x | -28.4 x | -53.3 x | -15.5 x | -9.7 x | -25.6 x | 55.4 x | -16.6 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | 9.57 x | - |
| EV / Revenue | - | - | - | - | - | - | 9.57 x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | -33,366,415 x | -15,363,989 x | - | - | - | - |
| FCF Yield | - | - | -0% | -0% | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 17,219 | 34,954 | 40,017 | 41,726 | 42,174 | 47,976 | - | - |
| Reference price 2 | 5.200 | 6.820 | 43.70 | 29.54 | 22.51 | 19.94 | 19.94 | 19.94 |
| Announcement Date | 3/26/20 | 3/23/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 100 | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -4.959 | -6.446 | -32.87 | -80.02 | -106 | -88.45 | -20.25 | -119.6 |
| Operating Margin | - | - | - | - | - | - | -20.25% | - |
| Earnings before Tax (EBT) 1 | -4.631 | -6.334 | -32.38 | -76.25 | -97.22 | -37.05 | 31.2 | -67.2 |
| Net income 1 | -4.631 | -6.334 | -32.38 | -76.25 | -97.22 | -37.05 | 17.75 | -67.2 |
| Net margin | - | - | - | - | - | - | 17.75% | - |
| EPS 2 | -0.2700 | -0.2400 | -0.8200 | -1.900 | -2.320 | -0.7800 | 0.3600 | -1.200 |
| Free Cash Flow | - | - | -52.41 | -80.23 | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/26/20 | 3/23/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -14.44 | -17.82 | -19.92 | -21.34 | -20.94 | -26.51 | -28.78 | -27.88 | -22.79 | -19.93 | -21.1 | -22.6 | -24.8 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -14.17 | -17.53 | -19.33 | -20.26 | -19.13 | -24.27 | -26.38 | -25.65 | -20.92 | 25.04 | -18.8 | -20.55 | -22.7 |
| Net income 1 | -14.17 | -17.53 | -19.33 | -20.26 | -19.13 | -24.27 | -26.38 | -25.65 | -20.92 | 25.04 | -18.8 | -20.55 | -22.7 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.3500 | -0.4400 | -0.4800 | -0.5100 | -0.4700 | -0.5800 | -0.6300 | -0.6100 | -0.5000 | 0.5800 | -0.4000 | -0.4200 | -0.4550 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/28/22 | 5/5/22 | 8/4/22 | 11/7/22 | 2/28/23 | 5/1/23 | 8/3/23 | 11/7/23 | 2/28/24 | 5/10/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | -52.4 | -80.2 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | 22.2 | 2.71 | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 3/26/20 | 3/23/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
19.94
USD
Average target price
103
USD
Spread / Average Target
+416.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.42% | 992M | |
| +19.33% | 125B | |
| +13.95% | 109B | |
| -3.53% | 24.74B | |
| +2.71% | 22.67B | |
| -9.95% | 18.14B | |
| -41.48% | 16.67B | |
| -12.62% | 16.64B | |
| +0.99% | 13.45B | |
| +21.79% | 11.32B |
- Stock Market
- Equities
- SAVA Stock
- Financials Cassava Sciences, Inc.
